Astal Laboratories Limited has submitted its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, to the Bombay Stock Exchange. The filing serves as a formal notification of the company’s compliance with disclosure norms under the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The company informed the exchange that the extract of the financial results was published in the August 15, 2026 editions of The Financial Express and The Business Standard (English) and The Jansatta (Hindi). This publication fulfills the requirement under Regulation 47 of the SEBI LODR Regulations.

Regulatory Compliance

The submission was made pursuant to Regulation 30 of the SEBI LODR Regulations, which mandates timely disclosure of financial performance to listed entities. Astal Laboratories provided copies of the relevant newspaper publications to the exchange for record-keeping purposes.

Mahendra Kumar, Company Secretary and Compliance Officer at Astal Laboratories, signed the submission on August 16, 2026. The company previously operated under the name Macro International Limited.

What the Numbers Show

The current filing is a procedural notice confirming the publication of financial results. It does not contain specific financial metrics such as revenue, profit, or cash flow figures. Investors must refer to the full detailed format filed with the stock exchange or the published newspaper extracts for granular financial data.

Astal Laboratories Ltd has authorised the evaluation of potential acquisitions to expand its manufacturing capacity and strengthen its global market presence. The board approved initiating discussions to acquire one or more pharmaceutical manufacturing units in India that are compliant with USFDA, EU-GMP, or WHO/GMP standards. This strategic move aims to meet rising order volumes. The company's market capitalisation currently stands at Rs. 90 crore.

Strategic Expansion

The board authorised Mr. Sudheer Karna Kankanala, Whole-time Director, to evaluate opportunities and negotiate the proposed acquisition of compliant manufacturing units. This initiative is intended to bolster the company's production capabilities to address increasing demand.

Fundraising Approval

To finance these initiatives, the board authorised Mr. Balayogiswara Rao Peddinti, Chief Financial Officer, to engage with investors and financial institutions. The company plans to raise an aggregate amount of up to Rs. 300 crore through various instruments.

Authorised Instruments

The fundraising may include one or a combination of the following:

The funds will be raised via private placement or other permissible modes, subject to statutory, regulatory, and shareholder approvals. The board meeting was held on June 29, 2026, at the company's corporate office in Telangana.